Contracts › 75N93023F00004
75N93023F00004: A Phase Ii, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of Novartis EYU688 Against Dengue Virus 2 Infection in a Controlled Human Infection Model in Healthy Adult Participants
Awarded to The Johns Hopkins University by National Institutes of Health (NIH).
$4.6Mobligated
$4.6Mpotential value
22 July 2026current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75N93023F00004 |
|---|---|
| Vehicle | 75N93019D00031 |
| Awardee | The Johns Hopkins University |
| Awarding agency | National Institutes of Health (NIH) |
| Awarding office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541714 Research and Development in Biotechnology (Except Nanobiotechnology) |
| PSC | AN43 Health R&D Services; Health Care - Other; Experimental Development |
| Place of performance | MD |
| Period of performance | 23 August 2023 to 22 July 2026 |
| Potential end | 22 July 2026 |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541714 contracts · All expiring contracts · USASpending record